LY2109761

inquiry

Cat No.

CEI-0313

Description

As a novel inhibitor, LY2109761 can TGF-beta receptor type I and TGF-beta receptor II with Ki of 38 nM and 300 nM, respectively.

CAS_No

700874-71-1

Molecular Weight

441.52

Purity

>99%

Storage

2 years at -20 centigrade

Targets

TGF-beta receptor I, TGF-beta receptor II

Molecular Formula

C26H27N5O2

Chemical Name

7-(2-morpholinoethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline

Solubility

DSMO

In vitro

LY2109761 treatment induces a dose-dependent low-anchorage growth inhibition of L3.6pl/GLT cells, leading to ~33% or 73% inhibition at 2 uM and 20 uM. And LY2109761 treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression.

In vivo

Administration of LY2109761 (50 mg/kg) alone or in combination with gemcitabine (25 mg/kg) significantly reduces the tumor volume by ~70% and ~90%. In consistent with the in vitro effect, administration of LY2109761 alone or in combination with radiation, markedly inhibits tumor growth in the orthotopical CSLC glioblastoma model by 43.4% and 76.3%, respectively.

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry